Sugi Predict

Sugi Predict / Compounds / SCHEMBL898346

SCHEMBL898346

SCHEMBL898346

CCc1ccc(C(C)(C)c2[nH]c3cc(C#N)ccc3c2C(=O)OC(C)(C)C)cc1I

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ GABRA1 P14867 7/20 0.34
▸ GABRG2 P18507 7/20 0.34
▸ GABRB3 P28472 7/20 0.34
▸ GABRA3 P34903 7/20 0.34
▸ GABRA2 P47869 7/20 0.34
▸ GABRA5 P31644 5/20 0.33
▸ GABRA6 Q16445 4/20 0.33
▸ GABRA4 P48169 3/20 0.33
▸ ALK Q9UM73 6/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.32
▸ CSNK1A1 P48729 1/20 0.32
▸ CSNK1D P48730 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ CSNK1G2 P78368 1/20 0.32
▸ EML4 Q9HC35 3/20 0.32
▸ SRPK2 P78362 2/20 0.31
▸ SRPK1 Q96SB4 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL898010 0.92 L3MBTL1 (0.36) L3MBTL1ALKIRAK4CSNK1A1CSNK1D
SCHEMBL28351222 0.91 L3MBTL1 (0.36) L3MBTL1GABRA1GABRG2GABRB3GABRA3
SCHEMBL24676748 0.91 L3MBTL1 (0.37) L3MBTL1GABRA1GABRG2GABRB3GABRA3
SCHEMBL31540875 0.89 L3MBTL1 (0.36) L3MBTL1GABRA1GABRG2GABRB3GABRA3
SCHEMBL31507391 0.89 L3MBTL1 (0.37) L3MBTL1GABRA1GABRG2GABRB3GABRA3
SCHEMBL28319539 0.89 L3MBTL1 (0.38) L3MBTL1ALKIRAK4CSNK1A1CSNK1D
SCHEMBL23639626 0.88 L3MBTL1 (0.39) L3MBTL1GABRA1GABRG2GABRB3GABRA3
SCHEMBL31540879 0.83 CDK2 (0.32) L3MBTL1GABRA1GABRG2GABRB3GABRA3
SCHEMBL18531371 0.82 L3MBTL1 (0.39) L3MBTL1ALKCSNK1A1CSNK1DGSK3B
SCHEMBL24676630 0.82 L3MBTL1 (0.38) L3MBTL1ALKIRAK4CSNK1A1CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025067412-A1 PREPARATION METHOD FOR ANTI-TUMOR DRUG INTERMEDIATE 重庆博腾制药科技股份有限公司 2025-04-03 — — WO disclosed
EP-3848361-B1 METHOD OF PRODUCING TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-01-22 — — EP disclosed
CN-112585126-B Process for preparing tetracyclic compounds 中外制药株式会社 2024-05-07 — — CN disclosed
US-11939322-B2 Method for producing tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-03-26 — — US disclosed
CN-115677659-B Preparation method of aletinib 枣庄市润安制药新材料有限公司 2024-03-22 — — CN disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
CN-115677659-A Preparation method of erlotinib 枣庄市润安制药新材料有限公司 2023-02-03 — — CN disclosed
US-20220372025-A1 METHOD FOR PRODUCING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-11-24 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
EP-3848361-A1 METHOD OF PRODUCING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-07-14 — — EP disclosed
US-20170247352-A1 METHOD FOR PREPARING ALECTINIB SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) 2017-08-31 — — US disclosed
US-9573932-B2 Synthesis of intermediates in the preparation of ALK inhibitor XU YONG (US) 2017-02-21 — — US disclosed
US-20160340308-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-24 — — US disclosed
US-9440922-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-13 — — US disclosed
EP-2441753-B1 TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-03-30 — — EP disclosed
EP-2975024-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-20 — — EP disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220372025-A1 METHOD FOR PRODUCING TETRACYCLIC COMPOUND CYP1B1, CYP4B1, PAICS L3MBTL1 3768/4885GABRA1 844/4885GABRG2 1167/4885
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885
US-20170247352-A1 METHOD FOR PREPARING ALECTINIB ADH1C, ADH1A, ALK L3MBTL1 4358/4885GABRA1 2551/4885GABRG2 3219/4885
US-20160340308-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885
US-11939322-B2 Method for producing tetracyclic compound CYP1B1, CYP4B1, PAICS L3MBTL1 3768/4885GABRA1 844/4885GABRG2 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.